10:48 AM EDT, 04/22/2024 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Monday it will work with Genetika+ on Alzheimer's disease drug development, starting with the former's ongoing phase 2 clinical trial.

The study will help evaluate the therapeutic potential of NeuroSense's PrimeC therapy in treating Alzheimer's disease. It will comprise 20 patients with mild to moderate non-familial Alzheimer's disease, the company said.

NeuroSense shares were down more than 5% in recent trading.